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ABSTRACT.  1 
Limited data are available concerning differences in clinical outcomes of real-life patients 2 
treated with Ticagrelor and Prasugrel after PCI. 3 
Objective: To determine and compare efficacy and safety of Ticagrelor and Prasugrel in a 4 
real-word population. 5 
Design: RENAMI is a retrospective, observational registry. Data and outcomes of patients 6 
with acute coronary syndrome who underwent PCI and discharged with DAPT between 7 
January 2012 and January 2016 were included. The mean follow-up period was of 17±9 8 
months. 9 
Setting: 11 university hospitals from 6 European countries participated. 10 
Participants: Consecutive patients with ACS discharged with DAPT after primary PCI 11 
were enrolled. After propensity-score matching there were no substantial differences in the 12 
baseline clinical and interventional features.  13 
Exposures: All patients were treated with acetylsalicylic acid plus prasugrel (10 mg o.d.) 14 
or plus ticagrelor (90 mg b.d.). Mean duration of DAPT was 12.04±3.4 for patients treated 15 
with prasugrel and 11.90±4.1 months for ticagrelor (p 0.47). 16 
Main outcomes and measures: Long-term NACE was the primary end-point, while 17 
MACEs the secondary ones, along with their single components. Subgroup analysis for 18 
freedom from NACE and MACE were performed according to length of DAPT and to 19 
clinical presentation (STEMI-ACS) vs (NSTEMI-ACS). 20 
Results: 4244 patients (1699 in ticagrelor and 2275 in prasugrel group) were enrolled. 21 
After propensity-score matching 1290 patients of each cohort were included in the 22 
analysis. At 12 months, the incidence of NACE was lower in prasugrel patients (5.3% vs. 23 
8.5%, p 0.0001), as that of MACE (6.05% vs. 8.1%, p 0.001), mainly driven by a reduction 24 
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in recurrent MI (2.4% vs. 4.0%, p 0.029) and a lower rate of BARC 3-5 bleeding (1.5% vs. 1 
2.9%, p 0.011). The benefit of prasugrel was confirmed for NSTEMI patients and for those 2 
discharged with a DAPT regimen of 12 months or less. Only a trend in reduction for of 3 
NACE and MACE was noted for STEMI or for those treated with longer DAPT.  4 
Conclusions and relevance: The comparison between the drugs suggests better efficacy 5 
and safety of prasugrel versus ticagrelor used in combination with aspirin after NSTEMI, 6 
while not in STEMI patients. No differences were found for events occurring after 12 7 
months. Due to the non-randomized design of the present research, further studies 8 
are warranted to support these findings. 9 
 10 
KEY MESSAGES 11 
- Dual antiplatelet therapy is a cornerstone of the treatment of acute coronary 12 
syndromes but evidences comparing ticagrelor vs prasugrel in the real life 13 
setting are missing 14 
- According to the results of this observational study, prasugrel is safer and 15 
more effective than ticagrelor in NSTEMI patients with a reduction of re-16 
infarction and major bleeding after a follow up of 12 months. 17 
- In STEMI patients and in the subgroup of patients treated with a long DAPT 18 










1. Introduction 3 
Acute Coronary Syndromes (ACS) represent the most common clinical presentation 4 
for patients with CAD (Coronary Artery Disease) leading to a high risk of mortality and 5 
morbidity (1-4). 6 
From an interventional point of view, PCI (Percutaneous Coronary Intervention) 7 
improved the prognosis of these patients, thanks to technological improvement also in high 8 
risk anatomic settings (5-7). Regarding Dual AntiPlatelet Therapy (DAPT), the most 9 
debated questions are related to its length (8-11) and to the choice of the new antiplatelet 10 
agents (prasugrel and ticagrelor) which in randomized controlled trials (RCTs) offered a 11 
reduction of recurrent ischemic events despite a higher risk of bleeding (12,13). 12 
Both ticagrelor and prasugrel were found to be superior to clopidogrel for the 13 
treatment of ACS after PCI, showing some differences in their effect that may be related to 14 
the study design, but potentially also to the different drug formulation (14). Actually, from a 15 
pharmacodinamic point of view, level of antiaggregation did not differ in most of the 16 
reported studies (15). From a clinical point of view, randomized controlled trial on this topic 17 
did not show any difference, although underpowered especially due to low rate of events in 18 
a selected population (16). In most of the observational reports, prasugrel and ticagrelor 19 
have been compared to clopidogrel, showing a better efficacy and safety profile, while 20 
direct comparisons are limited by 30 days follow up or mostly focused on economic point 21 
of views (17,18). Another RCT designed to directly compare the two drugs in terms of 22 
clinical outcome is ongoing, but partial results have not been anticipated (19). 23 
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Consequently we performed the RENAMI, (REgistry of New Antiplatelets in patients 1 
with Myocardial Infarction) to allow a real life comparison between these such diffused  2 
new antiplatelet medicaments. 3 
 4 
2. Methods 5 
2.1 Study population. 6 
RENAMI (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction) 7 
is a retrospective, observational, multicenter, and international registry, in which 11 centers 8 
from 6 European countries (Spain, Italy, Switzerland, Greece, Serbia, United Kingdom) 9 
have voluntarily participated. RENAMI is an unfunded registry whose aim was to expand 10 
the knowledge about the long-term ischemic and hemorrhagic outcomes of patients 11 
discharged with DAPT with prasugrel or ticagrelor. All participating centers were university 12 
hospitals that had 24-hour catheterization laboratory, with internal clinical databases for 13 
ACS patients. Patients with ACS who underwent PCI and were discharged with DAPT with 14 
acetylsalicylic acid plus prasugrel (10 mg o.d.) or plus ticagrelor (90 mg b.d.) between 15 
January 2012 and January 2016 were consecutively included in the registry by the 16 
different participating centers. 17 
ACS were classified as acute myocardial infarction (AMI) with persistent ST-segment 18 
elevation (STEMI), AMI without persistent ST segment elevation (NSTEMI) and unstable 19 
angina, based on the definitions from clinical practice guidelines (20-21). The diagnoses of 20 
AMI were based on the universal definition of AMI (22). The diagnosis of unstable angina 21 
was established in the presence of suggestive symptoms or objective evidence of 22 
myocardial ischemia in the stress test, together with the detection of a significant stenosis 23 
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in the coronary angiography (≥ 70%, except for left main coronary artery, where the cut-off 1 
is ≥ 50%). 2 
Given the retrospective nature of the RENAMI registry, the diagnostic and therapeutic 3 
procedures were performed according to the protocols and preferences of each center and 4 
each physician.  5 
For the purpose of RENAMI, a database was specifically designed and sent to each of the 6 
11 participating centers. This database included information about clinical, analytical, 7 
echocardiographic, and angiographic variables, as well as follow-up data in terms of 8 
mortality, ischemic events and hemorrhagic events. The completed databases from each 9 
center were sent in an encrypted way to the coordination centers, University Hospital from 10 
Turin and University Hospital Álvaro Cunqueiro from Vigo, where they were merged into a 11 
single registry. The analysis of this registry for this study was carried out by 3 investigators 12 
from University Hospital from Turin. All of these steps were performed in accordance with 13 
the rules of Helsinki Declaration. The registry was approved by the local ethics committees 14 
of each center. 15 
2.2 End points. 16 
Long term NACE (Net Adverse Clinical Events, a composite end point of all cause 17 
death, mi and barc 3-5 bleedings) was the primary end point, while MACE (Major Adverse 18 
Clinical Events, a composite end point of all cause death, MI and ST) the secondary ones, 19 
along with their single components, and all cause bleeding. Subgroup analysis for freedom 20 
from NACE and MACE were performed according to length of DAPT and to clinical 21 
presentation (STEMI-ACS) vs. (NSTEMI-ACS). All events were right censored at 12 22 
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months, while a sub group analysis was performed for events occurring after 12 months 1 
only for patients with prolonged DAPT.  2 
2.3 Statistical analysis. 3 
Continuous variables are presented as means ± standard deviation or median with the 4 
interquartile range (IQR) and categorical variable are presented as frequency (%). 5 
Categorical variables were compared with the Fisher’s exact test. Parametric distribution 6 
of continuous variables was tested graphically and with Kolmorogov Smirnov, and the 7 
appropriate analyses were used in accordance with the results. For propensity score, first 8 
logistic regression analysis was done for all baseline features that differed between aspirin 9 
and DAT and matching was computed after division into quintiles and methods of nearest 10 
neighbor on the estimated propensity score (23). Calibration was tested with Hosmer-11 
Lermeshow, and accuracy was assessed with Area Under the Curve. Standardized 12 
differences were evaluated before and after matching to evaluate performance of the 13 
model. The cumulative incidences of NACE and MACE were calculated using the Kaplan-14 
Meier method using length of DAPT as median follow up analysis and differences among 15 
groups were analyzed using a stratified log-rank test. Cox multivariate analysis on data 16 
before propensity score were performed with NACE and MACE as dependent 17 
variables. All statistical analyses were performed with SPSS 21 and differences were 18 









3. Results 3 
3.1 Baseline features and outcomes before propensity score with matching  4 
A total of 1699 patients were enrolled in the Prasugrel group and 2725 in the 5 
Ticagrelor group (see Figure number 1). The two populations significantly differed for the 6 
prevalence of some cardiovascular risk factors since patients in the Ticagrelor group were 7 
more frequently smokers (31% vs 19.3%, p<0.001), more often had arterial hypertension 8 
(56.4% vs 50.3%, p<0.001), diabetes (31.6% vs 27.2%, p=0.002) and dyslipidaemia 9 
(55.3% vs 51.4%, p=0.012) compared with Prasugrel group. Moreover a higher number of 10 
female (24.1% vs 15.7%, p<0.0001), patients older than 75 years old (17.8% vs 5.7%, p 11 
<0.0001) and with an impaired LVEF (10.9% vs 7.8%, p=0.007) could be notice in the 12 
Ticagrelor group. Clinical presentation was slightly different with a lower prevalence of 13 
STEMI (72.9% vs 48.8%, p<0.0001) in patients committed to Ticagrelor, although this 14 
group had more frequently a multivessel disease (47.1% vs 41.7, p=0.002) and a known 15 
history of CAD (25.4% vs 17.4%, p<0.0001, see Appendix, web only, Tables  S1 and 16 
S2). A complete revascularization was achieved in 82.9% of patients in the ticagrelor 17 
group, whereas in the prasugrel group in the 76.8% of the cases (p<0.0001). DES were 18 
significantly more used in the ticagrelor group (68.9% vs 60.6%, p<0.0001) compared with 19 
the prasugrel group. However, patients enrolled in the latest, received more frequently a 20 
pre-treatment with GP IIB-IIIa inhibitors (28.6% vs 16.2%, p>0.0001) and thrombus 21 
aspiration (38.1% vs 20.3% p<0.0001). At discharge, length of DAPT was slightly longer in 22 
prasugrel (12.89±3.6 for patients treated with prasugrel and 11.33±3.5, p<0.001). 23 
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A comparison between standardized difference for baseline and interventional features of 1 
patients before and after propensity score with matching is provided in table S1a and S2a 2 
respectively (see appendix, web only). 3 
A lower incidence of in-hospital adverse events was recorded among patients enrolled in 4 
Prasugrel group. In particular rates of IH-Re-AMI (0.8% vs 1.7%, p =0.012), IH-Stroke (0% 5 
vs 0.6%, p=0.002) and IH bleeding (2.3% vs 3.7%, p=0.008) were significantly inferior, 6 
although this had no impact on MACEs (4.8% vs 4.4%, p=0.47) or all-cause death (2.6% 7 
vs 2.1%, p=0.32, see Appendix, web only Table S3). Indeed, after a mean follow up of 8 
17±9 months, no difference of statistical meaning was observed in the frequency of the 9 
main outcomes investigated between the two enrolled populations.  10 
3.2 Baseline features and outcomes after propensity score with matching  11 
After propensity score with matching 1290 patients of each cohort were included in 12 
the analysis (see Figure n 1). There were no substantial differences in the baseline 13 
clinical and interventional features, most of patients being men, with a relevant burden of 14 
CV risk factors and presenting most frequently with STEMI (see Tables 1 and 2). Length 15 
of DAPT was 12.04 ± 3.4 for patients treated with prasugrel and 11.90 ± 4.1 months for 16 
ticagrelor (p 0.47). After propensity score with matching (see Table 3a) at 12 months, 17 
incidence of NACE was lower in prasugrel patients (5.3% vs. 8.5%, p 0.0001), as that of 18 
MACE (6.05% vs. 8.1%, p 0.001), mainly driven by recurrent MI (2.4% vs. 4.0%, p 0.029) 19 
and BARC 3-5 bleedings (1.5% vs. 2.9%, p 0.011, see fig n 2). No differences were found 20 
for events occurring after 12 months for patients with prolonged DAPT (see Table 3b and 21 
Figure 3). Kaplan-Meier analysis was performed for NACE and MACE (see figure 4), 22 
confirming the overall trend in favor of prasugrel.  23 
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Benefit of prasugrel for NACE and MACE was confirmed for patients treated with a 1 
DAPT of 12 months or less (median 12, 11-13 I and III IQR), while only a trend was noted 2 
for those treated with longer DAPT (median 16, 13-18 I and III IQR) (see figure 5). 3 
Regarding clinical presentation, STEMI patients did not show significant difference at 4 
survival analysis, while those presenting with NSTEMI derived more benefit from prasugrel 5 
(see figure 6). The same results were confirmed at multivariate analysis for NACE 6 
and MACE as dependent variable (see appendix, web only tables 1 and 2). 7 
4. Discussion. 8 
The present observational study provides a real-word head-to-head comparison of 9 
the efficacy and safety of ticagrelor versus prasugrel in a contemporary European cohort 10 
of patients with ACS undergoing PCI. After propensity score matching, we have found that 11 
DAPT with prasugrel was associated with significantly less incidence of ischemic and 12 
bleeding events, during a follow-up period of 17 ± 9 months. Interestingly, this reported 13 
benefit was concentrated in NSTEMI patients, without differences in ischemic or bleeding 14 
outcomes in STEMI patients.  15 
Although the present study was not a randomized trial, the importance of its 16 
results lies in the limited scientific evidence currently available that directly 17 
compares DAPT with ticagrelor and prasugrel. Physicians are increasingly being 18 
confronted with the need to select a P2Y12 antagonist as part of the daily care of ACS 19 
patients. ESC guidelines recommended DAPT with ticagrelor or prasugrel instead of DAPT 20 
with clopidogrel, in absence of contraindications (9). DAPT with clopidogrel has been 21 
relegated to those ACS patients who cannot receive ticagrelor or prasugrel, including 22 
those with prior intracranial bleeding or indication for OAC. In their pivotal clinical trials 23 
(PLATO and TRITON-TIMI 38), both ticagrelor and prasugrel have been shown to reduce 24 
11 
 
ischemic events against clopidogrel, with consequent increased hemorrhagic risk (12,13) 1 
These data, together with the recommendations of clinical practice guidelines (9,22), could 2 
suggest that ticagrelor and prasugrel could be interchangeable. Even with the more 3 
marked bleeding risk reported with prasugrel in TRITON-TIMI 38, specially in high risk 4 
patients (prior stroke, <60 kg,> 75 years) (12), the routine clinical practice could tend to 5 
favor the use of ticagrelor. However, very few studies have directly compared the efficacy 6 
and safety of ticagrelor versus prasugrel in patients with ACS (16, 18, 25-27). Our study 7 
provides more evidence in this issue, and our results must be faced with data from the few 8 
studies published to date about this topic.  9 
There is only one randomized clinical trial that compared prasugrel and ticagrelor in ACS 10 
patients, which is the PRAGUE-18 trial, that has not found significant differences in 11 
adverse outcomes between DAPT with ticagrelor and DAPT with prasugrel (16). This is a 12 
randomized, multicenter study designed to compare the efficacy and safety of prasugrel 13 
and ticagrelor in patients with AMI treated with primary or immediate PCI. The PRAGUE-14 
18 trial included 1,230 STEMI and very-high risk NSTEMI patients (634 with prasugrel, 596 15 
with ticagrelor). At 30 days, there was no difference in all-cause mortality, non-fatal AMI, 16 
stroke and stent thrombosis. There were also no differences in bleeding rates based on 17 
the TIMI definition or on the BARC definition. Despite the potential limitations regarding 18 
the non-randomized design of the present analysis, our results are somewhat in line 19 
with those of the PRAGUE-18 clinical trial, since we have not found differences in adverse 20 
events for patients with STEMI, and in PRAGUE-18 trial, most of patients (90%) had 21 
STEMI. The benefit of DAPT with prasugrel versus DAPT with ticagrelor that we found was 22 
focused on patients with NSTEMI, who were only 5% in the PRAGUE-18 trial and were not 23 
specifically analyzed for low-size samples (n < 100). A possible explanation of this finding 24 
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could also lie in the different physiopathology of the two different ACS syndromes. STEMI, 1 
from an epidemiological point of view, is in fact more often a monovessel disease whereas 2 
NSTEMI patients frequently report a multivessel pathology (28). This could have resulted 3 
in a low number of vessels treated and stent implanted in STEMI patients, probably not 4 
enough to bring out differences of statistical meaning. 5 
In addition to the PRAGUE-18 trial data, there is also a retrospective observational study 6 
that performed a "real-world" comparison of prasugrel and ticagrelor in ACS patients. This 7 
is the study of Larmore et al. (18), that has shown net benefit at 3 months of DAPT with 8 
prasugrel versus DAPT with ticagrelor. It is an observational study, using a payer database 9 
from United States, with 16,098 ACS patients (<40% STEMI) undergone PCI (13,134 with 10 
prasugrel, 2,964 with ticagrelor). After propensity score matching, 90-days net adverse 11 
clinical events (NACE) was 22% lower in prasugrel-treated than in ticagrelor-treated 12 
patients (RR 0.78; 95% CI, 0.64–0.94), with less mortality, myocardial infarction and 13 
severe bleeding (defined as ≥ 3 or 4 transfusions, intracranial bleeding or bleeding leading 14 
to death within 72 hours). Therefore, in a population in which NSTEMI predominates, the 15 
results of a lower rate of NACE with DAPT with prasugrel versus DAPT with ticagrelor are 16 
consistent with those of our study. Moreover, using another US-database (ProMetis-Lx) 17 
with approximately 60% of NSTEMI, Simeone JC et al. (25) have found a higher 1-year 18 
healthcare resource utilization (HRU) with ticagrelor than with prasugrel, primarily driven 19 
by cardiovascular causes (all over congestive heart failure), although with no significant 20 
difference in bleeding HRU.  21 
Considering the presented studies and our data, it seems reasonable to hypothesize that 22 
DAPT with prasugrel may be superior in terms of safety and efficacy to DAPT with 23 
ticagrelor in patients with NSTEMI, with no differences between the two drugs in patients 24 
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with STEMI. It is difficult to give an explanation to these unexpected findings, although 1 
consistent with current scientific evidence. With the current approved maintenance dosing 2 
for both drugs, adequate levels of platelet inhibition are achieved in over 90% of patients 3 
(29-31). However, the finding of significantly lower rates of ischemic events associated 4 
with prasugrel in NSTEMI patients, common with the results of Larmore et al. (18), is also 5 
directionally in line with two meta-analyses (26-27). In them, using PLATO and TRITON-6 
TIMI 38 data, making indirect comparisons between ticagrelor and prasugrel, it was shown 7 
a greater ischemic protection with DAPT with prasugrel versus DAPT with ticagrelor, 8 
especially in the reduction of stent thrombosis, with no difference in non-CABG bleeding 9 
rates (26-27). The more extended explanation is based on the ticagrelor-induced non-10 
platelet side effects, in particular the onset of dyspnea, and of a twice-daily dosing regimen 11 
on medication adherence and discontinuation, factors that may confer an increased risk for 12 
subsequent cardiac events, especially given the more rapid offset of the antiplatelet effect 13 
of ticagrelor (14). However, the finding of lower bleeding rates in NSTEMI patients treated 14 
with Prasugrel results more difficult to explain. Larmore at al. (18), who in their study found 15 
the same data, suggested that the different dosages of ASA used in the different countries, 16 
not recorded in their database, could have contributed to the final outcome. Higher doses 17 
could have obviously conferred an higher bleeding risk on one hand, but, on the other, 18 
PLATO study demonstrated reduced efficacy of ticagrelor with high-dose aspirin thus 19 
increasing the thrombotic risk as well. Finally it can not be excluded that differences in 20 
prescribility of the two drugs could have influenced the results obtained, since both 21 
Prasugrel and Ticagrelor are contraindicated in patients with active bleeding, but the 22 
former is to be avoided in patients with previous TIA or stroke, thus probably contributing 23 
to select a population with a lower hemorrhagic and thrombotic risk. 24 
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4.1 Limitations 1 
While an important strength of this study is the use of a multicentric database that capture 2 
patients from 6 European countries, several limitations need to be considered when 3 
interpreting the data. First, those that are inherent to retrospective studies. Second, this is 4 
not a RCT; although propensity-score matching was used to adjust baseline differences, 5 
residual confounding may remain due to the potential imbalance of unknown and 6 
unmeasured known confounders (e.g., socioeconomic status, access to care, provider 7 
characteristics, therapy adherence…) between treatments groups, consequently results 8 
have to be interpreted with caution. Despite all the patients enrolled were managed 9 
according the most recent available ESC guidelines for clinical practice, we 10 
acknowledge the lack of a specific analysis aimed to investigate differences in 11 
diagnostic and therapeutic approaches among participating centers. Finally, 12 
missing about baseline and procedural features were less than 5%, while less than 13 
10% for outcomes, supporting our results. In the context of these limitations, our 14 
finding should be considered as hypothesis-generating, and should encourage to conduct 15 
further head-to-head randomized trials. 16 
5. Conclusions 17 
 Results of the present retrospective, observational, propensity-adjusted study 18 
suggest a better efficacy and safety profile of prasugrel as compared to ticagrelor in 19 
real-life ACS patients treated with primary PCI and DAPT. At subgroup analysis 20 
according the clinical presentation and DAPT duration, the benefit of prasugrel was 21 
confirmed in NSTEMI patients and in those treated with a 12 months or shorter 22 
DAPT, but not in STEMI patients or in those treated with long DAPT regimen.  23 
Further RCT are warranted to support these results. 24 
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Figures caption and legends 20 
 21 
Figure 1 caption: design of the study. 22 
Figure 2 caption: 12 months outcomes after propensity score with matching.  23 
Legend: BARC = Bleeding Academic Research Consortium; MACE = Major adverse 24 
cardiovascular events; MI= Myocardial infarction; NACE = net adverse clinical events; ST= 25 
stent thrombosis  26 
 Figure 3 caption: Outcomes after 12 months (median 19:13-22) for patients with DAPT 27 
longer than 12 months after propensity score with matching. 28 
20 
 
Legend: BARC = Bleeding Academic Research Consortium; MACE = Major adverse 1 
cardiovascular events; MI= Myocardial infarction; NACE = net adverse clinical events;; 2 
ST= stent thrombosis 3 
Figure 4 caption: Kaplan Meier for survival from NACE (above) and MACE (below) 4 
Figure 5 caption: Kaplan Meier for survival from NACE (right) and MACE (left) for patients 5 
with with DAPT of 12 months (above) and longer (below). 6 
Figure 6 caption: Kaplan Meier for survival from NACE (right) and MACE (left) for STEMI 7 
(above) and NSTEMI-ACS (below). 8 
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